An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
复制标题
DOI：
10.1007/s00520-014-2326-9
复制
发表时间：
2015-01
影响因子：
3.1
通讯作者：
Loprinzi, Charles L.
中科院分区：
文献类型：
--
作者：
Hegerova, Livia T.;Leal, Alexis D.;Grendahl, Darryl C.;Seisler, Drew K.;Sorgatz, Kristine M.;Anderson, Kari J.;Hilger, Crystal R.;Loprinzi, Charles L.
福沙匹坦是一种止吐药，用于治疗化疗引起的恶心和呕吐。我们最近报告，一组接受阿霉素和环磷酰胺 (AC) 化疗的乳腺癌患者的输注部位不良事件 (ISAE) 有所增加。在本研究中，我们评估了福沙匹坦与非蒽环类铂类抗肿瘤方案联合使用的静脉毒性。对 2011 年 1 月 1 日或之后在罗彻斯特梅奥诊所接受高度致吐化疗的患者中开始使用福沙匹坦的首批 81 名患者进行了回顾性审查。这些方案均不包含蒽环类药物。收集的数据包括基线人口统计、化疗方案、静脉通路类型和 ISAE 的严重程度。将这些患者的数据与之前收集的接受 AC 治疗的患者的数据进行比较。使用 χ2 和单变量逻辑回归进行统计分析来评估治疗方案、福沙匹坦与 ISAE 风险之间的关联。在这 81 名患者中，非蒽环类铂组的 ISAE 发生率为 7.4%。最常见的 ISAE 是肿胀 (3%)、外渗 (3%) 和静脉炎 (3%)。按治疗方案分层时，与铂类药物组相比，蒽环类药物组中福沙吡坦与 ISAE 风险显着增加相关（OR 8.1；95% CI 2.0–31.9）。福沙匹坦止吐治疗导致显着的 ISAE，明显高于以前的报告。接受铂类化疗的患者的 ISAE 似乎比接受蒽环类药物治疗的患者要少。
Fosaprepitant is an antiemetic used for chemotherapy-induced nausea and vomiting. We recently reported increased infusion site adverse events (ISAE) in a cohort of breast cancer patients receiving chemotherapy with doxorubicin and cyclophosphamide (AC). In this current study, we evaluated the venous toxicity of fosaprepitant use with non-anthracycline platinum-based antineoplastic regimens. A retrospective review was conducted of the first 81 patients initiated on fosaprepitant among patients receiving highly emetogenic chemotherapy, on or after January 1, 2011 at Mayo Clinic Rochester. None of these regimens included an anthracycline. Data collected included baseline demographics, chemotherapy regimen, type of intravenous access and type, and severity of ISAE. Data from these patients were compared to previously collected data from patients who had received AC. Statistical analysis using χ2 and univariate logistic regression was used to evaluate the association between treatment regimen, fosaprepitant, and risk of ISAE. Among these 81 patients, the incidence of ISAE was 7.4 % in the non-anthracycline platinum group. The most commonly reported ISAE were swelling (3 %), extravasation (3 %), and phlebitis (3 %). When stratified by regimen, fosaprepitant was associated with a statistically significant increased risk of ISAE in the anthracycline group (OR 8.1; 95 % CI 2.0–31.9) compared to the platinum group. Fosaprepitant antiemetic therapy causes significant ISAE that are appreciably higher than previous reports. Patients receiving platinum-based chemotherapy appear to have less significant ISAE than do patients who receive anthracycline-based regimens.
登录
查看更多内容
影响因子：
3.1
作者：
Rapoport, Bernardo L.;Jordan, Karin;Schmoll, Hans-Joachim
通讯作者：
Schmoll, Hans-Joachim
影响因子：
50.5
作者：
Roila, F.;Herrstedt, J.;Warr, D.
通讯作者：
Warr, D.
影响因子：
6.2
作者：
Herrington, Jon D.;Jaskiewicz, Adam D.;Song, Juhee
通讯作者：
Song, Juhee
影响因子：
45.3
作者：
Grunberg, Steven;Chua, Daniel;Herrstedt, Jorn
通讯作者：
Herrstedt, Jorn
影响因子：
2.9
作者：
Lasseter, Kenneth C.;Gambale, Jay;Murphy, M. Gail
通讯作者：
Murphy, M. Gail